fever Fever in patients with hematological malignancies can be either a feature of the underlying malignancy or a signal that urgent therapeutic intervention is needed for another reason than the hematological malignancy itself. The challenge to the clinician is to determine which of these alternatives applies to a given patient.
Fever of unknown origin is defined as prolonged fever of >3 weeks' duration and a temperature >38.3°C (101°F). In patients without known prior disease, the most likely causes of fever of unknown origin are infections, neoplasms or collagen vascular diseases. Of infections tuberculosis, intraabdominal abscesses, chronic cholecystitis, culture-negative endocarditis and other occult chronic infections are common. The most common tumors that cause fever of unknown origin are lymphomas, renal cell carcinomas and atrial myxomas considered to be due to cytokine production.
In chronic lymphocytic leukemia (CLL) and multiple myeloma, lungs, ears and disseminated sites are origins of infections and likely organism are Streptococcus pneumonia, Hemophilus influenza, and Neisseria meningitidis. In acute leukemias frequent sites of infections are skin, respiratory tract and GI tract. Aerobic gram-positive and gram-negative bacteria are prevailing ones.
Immediate institution of appropriate antibiotics is required in febrile patients, not only in the setting of profound neutropenia or after stem-cell transplantation but also when the patient has undergone splenectomy. A splenectomized patient with a fever is a medical emergency. After splenectomy, the patient may have an increased risk of having an infection. When the patient contracts an infection by encapsulated microorganisms, the loss of the spleen's function, a filter of blood-borne pathogens, enhances the risk of developing uncontrolled bacteremia. Because of the danger of such infections, it might be recommended that splenectomized patients keep oral antibiotics at home in case they are delayed in reaching an emergency room.
In case of elective splenectomy patients should be vaccinated before the surgical procedure against S. pneumonia. Postsplenectomy is recommended to revaccinate every fifth year or with a shorter interval depending on the serological response.
'B' symptoms
Approximately half of the patients with lymphomas have 'B' symptoms at the time of the diagnosis. 'B' symptoms include unexplained fever (temperature >38°C), night sweats and unexplained loss of >10% body weight within the preceding 6 months. Fever might be continuous or intermittent and may be low grade or >39°C. It is frequently unrecognized by the patient, and the only symptoms may be fatigue and malaise. Symptomatic night sweats should be drenching and characterized by soaking night clothes or sheets and not limited to perspiration. Differential diagnosis include above all various chronic infections as tuberculosis, toxoplasmosis, fungal infections and chronic viral infections. Pruritus can be a manifestation of a number of systemic diseases in the setting where there are no visible skin lesions. When a patient has generalized pruritus of unknown origin and no rash, a search for an underlying nondermatologic disease is required.
Several hematological malignancies might present with generalized pruritus without skin rash: polycythemia vera, Hodgkin's and non-Hodgkin's lymphomas, mastocytosis and cutaneous T-cell lymphomas. In polycythemia vera the pruritus is aquagenic i.e. after showering or bathing.
Differential diagnosis that should be in mind is endocrine disorders (i.e. thyreotoxicosis, hypothyroidism, diabetes), hepatobiliary obstruction, hepatic failure, chronic renal failure, drug reactions and various neurological disorders.
fatigue
Fatigue is a symptom that affects many aspects of the cancer patient's life, from being able to carry out everyday task to impaired relationships with family and friends. It should be pointed out that fatigue is not only due to decreased hemoglobin concentration but also due to hormonal imbalance. Fatigue is often linked to depression in cancer patients because low energy levels reduce the level of social interaction and increase the patient's sense of isolation. Fatigue should clearly be differentiated from asthenia which requires a different treatment approach.
Fatigue adversely affects daily life more than pain. Many physicians do not seem to realize the significant negative effect of fatigue on patients HRQoL (health related quality of life) partly as a result of possible underestimation of the severity of cancer-related fatigue but also due to the fact that many patients do not report fatigue. Common reasons for not reporting fatigue are the physician may not ask about it; the patient fears that treatment may be delayed or reduced lessening the chance of a favorable outcome; the assumption that the fatigue will disappear spontaneously; and a fear that it is caused by the cancer itself and that it is a symptom to be endured since there may be no available treatment.
A lack of knowledge among cancer patients and their caregivers regarding the importance of reporting fatigue and the availability of effective management options, such as erythropoietic agents and planned exercise programs, is also an important reason for not diagnosing the fatigue syndrome.
Several methods could be used to facilitate communication about fatigue between patients, caregivers and physicians. Physicians and other staff members working with cancer patients should be informed about HRQoL problems associated with fatigue and about management options. By asking the patient about fatigue regularly, the physician allows the patient to talk about this and related problems. Another option to reveal the patients' problems regarding fatigue is to use some of the HRQoL assessment forms on a regular basis. In the clinical setting, visual analog scale could be used when one assessment is compared with another by the same patient. Thus, the course of fatigue and related problems can be followed over time.
To measure fatigue, an instrument called Functional Assessment of Cancer Therapy General (FACT-G) has been developed to allow HRQoL to be assessed. Additional instruments have also been developed as FACT-F (F for fatigue) and FACT-An (An for anemia). These instruments include also in addition to fatigue, weakness, listlessness, tiredness, energy, ability to perform daily activities, limitation of social activities and need for sleep during the day. These instruments are considered to be reliable and valid for assessing HRQoL and fatigue, in patients with hematological malignancies, and for addressing the implications and consequences of fatigue in addition to symptom expression. Fatigue is an underestimated problem in patients with hematological malignancies and should be monitored in individual patients either by asking the patient about it regularly at follow-up visits or by using HRQoL instruments.
mucosal damage
Oral discomfort in patients with hematological malignancies arises from poor oral hygiene, mucositis, viral infections, candida infections, or dry mouth caused by mouth breathing, or medication for pain or other symptoms.
Candida presents as a burning tongue or pain when eating or swallowing; white plaques along the sides of the tongue or cheeks, or on the roof of the mouth; angular cheilitis or in denture wearers, red edematous areas. Topical antifungal agents can effectively treat mucositis from candida. Topical agents do not prevent esophageal candidiasis, which usually presents as a delayed pain that occurs after swallowing is located anywhere from the throat to the sternum.
bleeding
Bleeding complications may be due to imbalances in the plasmatic clotting system, abnormalities of platelet count or function, vascular defects or a combination of various factors. Liver infiltration by leukemia cells can decrease production of clotting factors, and acquired von Willebrand's disease as well as primary fibrinolysis may occur in association with leukemias apart from DIC (disseminated intravascular coagulation) (see below). Thrombocytopenia can occur as complication of the underlying hematological malignancy and also, albeit less frequently, due to immune-mediated thrombocytopenia. Abnormal platelet function is common in patients with myeloproliferative disorders, particularly in those with polycythemia vera. Paraproteinemia may lead to platelet coating and impaired platelet aggregation.
Symptoms depend on the extent of the bleeding disorder and may consist of epistaxis, hematuria, GI bleeding, petechiae or cerebral bleeding with headache and visual disturbances.
Acute leukemias are frequently associated with gingival and/or skin bleedings mainly due to thrombocytopenia. Skin bleedings may also be due to coagulation abnormalities or fragile vessels as in amyloidosis.
Upper gastrointestinal bleeding may be associated with hematological malignancies of GI lymphomas and variceal bleedings from portal hypertension due to myeloproliferative disorders polycythemia vera and myelofibrosis.
peritoneal and pleural effusions
Ascites is defined as the abnormal accumulation of fluid within the peritoneal cavity. The pathogenesis of malignant ascites has relatively little to do with sodium and water excess but rather is a consequence of a direct tumor cell invasion of subdiaphragmatic lymphatic vessels and consequent perversion of normal peritoneal lymphatic drainage. Hematological malignancies are not frequently associated with ascites but ascites can be noted in lymphomas and plasmocytomas.
Pleural effusion may be seen in multiple myeloma. Interestingly, myeloma cell lines can easily be established from pleural effusions while it is difficult from bone marrow myeloma cells.
Chylous pleural effusion may be due to thoracic lymphoma obstructing or infiltrating lymphatic vessels in the thoracic cavity.
lymphadenopathy
Lymph nodes can enlarge owing to polyclonal expansion/ infiltration of lymphocytes in response to infectious stimuli of infection or antigen exposure or as a component of autoimmune diseases. In lymphomas and leukemias, nodal enlargement is due to a monoclonal expansion of transformed lymphoid cells. Table 1 outlines disorders associated with lymphadenopathy. Cervical adenopathy is usually due to benign processes as infections of the upper respiratory tract. The main malignant diseases associated with cervical adenopathy are metastatic spread of head and neck, lung and thyroid cancers and malignant lymphomas.
Supraclavicular adenopathy is usually caused by malignancies or infections. Malignant causes include germ-cell tumors, gastrointestinal, lung, breast, head and neck carcinomas and lymphomas, whereas infectious etiologies include tuberculosis and toxoplasmosis and the immune disorder sarcoidosis.
Axillary adenopathy should include an evaluation for associated injury or infection of the upper extremities. If carcinoma is found in the lymph nodes both breasts need to be evaluated for breast cancer. Malignant lymphomas are also a common cause.
Inguinal lymphadenopathy may be due to sexually transmitted diseases, infections of the lower extremities or lymphomas. An occult lower extremity melanoma, genital tract and anus cancer should also be considered in the differential diagnosis.
Mediastinal and hilar adenopathies may be due to nonmalignant diseases as sarcoidosis (especially if it is bilateral). Unilateral hilar adenopathy can occur in tuberculosis and histoplasmosis as well as in lung and esophageal cancer. It is not usual in non-Hodgkin's lymphomas. Bilateral hilar adenopathy is most commonly due to Hodgkin's disease or sarcoidosis. Lymphomas, lung and esophageal cancer and germ-cell tumors may enlarge mediastinal lymph nodes.
Abdominal or retroperitoneal adenopathy is usually a manifestation of cancer. Germ-cell tumors, colorectal cancer, prostate cancer and lymphomas often involve the retroperitoneal lymph nodes.
Generalized lymphadenopathy including splenomegaly is suggestive of systemic illness and may be due to autoimmune disorders, sarcoidosis or infections as mononucleosis, toxoplasmosis, tuberculosis or Lyme disease. Lymphoproliferative disorders are the malignant diseases that are most commonly associated with generalized lymphadenopathy.
Lymph node bulky disease in patients with lymphoma may be of importance to define as this may have treatment implications (see below).
Lymph node biopsy is always warranted in the case of lymphadenopathy that develops over weeks to months, when a lymph node is >2 cm, when a lymph node is hard as rock and in lymphadenopathy with B symptoms, fatigue or cytopenias. Minimal additional evaluations to assess common causes of lymphadenopathy also include human immunodeficiency disease and hepatitis, medication review and complete blood count. Do not interpret a negative biopsy as anything more than not informative. Ensure appropriate follow-up of patients with negative biopsies. In selected patients fine needle aspiration biopsy might be sufficient.
splenomegaly
Splenic enlargement occurs in a number of hematological disorders. Patients who present with splenomegaly as their principal and/or sole abnormality do pose diagnostic challenges. Splenomegaly can result from the following problems: infiltration of granulomas, cancer, infections, deposition of proteins or lipids, elevated splenic venous pressure, extramedullary hematopoiesis in myeloproliferative syndromes and severe hemolytic anemias, splenic hyperplasia due to increased activity in clearing red blood cells (RBCs) in hemolytic anemias or secondary to lymphoid proliferation in response to viral infections and inflammatory as well as immunologic diseases. A list of potential causes is presented in Table 2 . The majority of patients with moderate splenomegaly are asymptomatic. Symptoms, when they occur, are generally related to splenic size such as early satiety, abdominal fullness and distention or pain from splenic infarction.
Up to 50% of moderately enlarged spleens are not palpable. Physical examination will detect splenomegaly only after the spleen has tripled in volume. Once the spleen has increased from its normal weight in the adult of 150-175 g to 450 g, it can be palpated anteriorly on abdominal examination. A common error is not palpating low enough in the abdomen to feel the edge of an enlarged spleen. Imaging modalities as computed tomography (CT) scan or ultrasound are often used to supplement the physical examination. Imaging of the spleen can determine the size of an impalpable but enlarged spleen.
Although cytopenias may be a manifestation of a primary hematologic disorder, reduction of the number of RBCs, platelets and/or white blood cells can also occur as a manifestation of hypersplenism. Hypersplenism can develop in patients who have splenomegaly due to splenic hyperplasia or infiltrative disease of the spleen, but it is more likely to appear in circumstances in which splenic venous pressure is increased, most commonly by cirrhosis of the liver. Reduced blood counts due to hypersplenism do not require therapy because the reductions are modest and the cells are still available if needed. The patient is generally not at risk for infection from leucopenia, bleeding from thrombocytopenia or symptoms from anemia. neurological symptoms Headache is a rare event in hematological malignancies. In nonHodgkin's lymphoma brain tumors can cause headache. Obstructive hydrocephalus may be caused by acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma. Extracranial causes of headache in myeloma may be explained by destruction of the calvarium of the upper cervical spine. Hyperviscosity may also induce headache in myeloma and Waldenström's macroglobulinemia.
Cranial neuropathies are uncommon complications. As the cranial nerves project from the brain stem via the subarachnoid space and skull base to the cranial tissues they can be damaged by a variety of malignant conditions either directly or indirectly. For example, tumor cell infiltration into the base of the skull or the leptomeningeal space can cause cranial nerve defects. In acute myelogenous leukaemia and ALL leukemic cell infiltration of the leptomeninges might occur. In intermediate and highgrade non-Hodgkin's lymphoma metastatic spread to the brain parenchyma and leptomeninges may cause cranial neuropathies. Magnetic resonance imaging is the optimal diagnostic procedure and cytology is confirmatory.
Encephalopathy is a nonspecific term for diffuse cerebral dysfunction. It is most commonly used to refer to patients with an acute confusional state. It is a rapidly developing, reversible change in behavior characterized by clouding of consciousness, incoherent train of thought and difficulty with attention and concentration. Encephalopathy may be encountered in leptomeningeal leukemic cell infiltration and hydrocephalus (see above). Metabolic encephalopathy may be due to hypercalcemia as a presenting symptom of multiple myeloma or increase in ammonia due to hepatic failure.
Peripheral neuropathy has a limited repertoire of clinical symptoms. The clinical features depend on which nerves are affected and whether sensory, motor or autonomic fibers are involved. Involvement of the peripheral nerves usually results in numbness, burning, parestesias and weakness. The distribution of the numbness or weakness depends on the nerves affected. Patients with peripheral neuropathies usually experience symmetric distal sensory loss and weakness, while patients with mononeuropathy will have asymmetric numbness and weakness in the distribution of specific peripheral nerves. Involvement of autonomic nerves may result in bladder and bowel dysfunction and postural hypotension. Most patients with peripheral neuropathies do not have cancer. The most common causes are diabetes, alcohol and peripheral nerve entrapment.
A small minority of patients presenting with neuropathies will have a previously undetected cancer as the underlying cause. Approximately 5% of patients with peripheral neuropathies have monoclonal gammopathy. Although most of these patients have monoclonal gammopathy of unknown significance, 10% will have multiple myeloma or Waldenström's macroglobulinemia. Patients with a known diagnosis of a hematological malignancy may have additional causes of neuropathies as malnutrition or compression neuropathies as in myeloma. Antimyelin antibodies may be another causative factor especially in monoclonal gammopathy. Hodgkin's disease has been associated with brachial neuritis and Guillain-Barré syndrome. Despite optimal treatment of the tumor most neuropathies tend to improve slowly or not at all. As a result, an important aspect of the management of patients with neuropathies is trying to treat the symptoms. Neuropathies associated with monoclonal gammopathy of undetermined significance very poorly respond to treatment attempts against immunoglobulinproducing cell clone.
pathologic fractures
A pathological fracture may represent the first sign of cancer, recurrence or disease progression. Pathological fractures represent a major threat to the patient's functional status.
There are various underlying causes of pathological fractures. Patients with osteopenia may develop fractures with minimal trauma. Hence, entities other than malignancy must be considered in the differential diagnosis as osteoporosis, osteomalacia, hyperparathyroidism, osteomyelitis, Paget's disease, etc. Of all pathological fractures 15%-20% represent benign disorders, 70% metastatic carcinomas and 10% myeloma/lymphoma.
The immediate management of pathological fractures is similar to management of other fractures. Spinal cord or nerve root compression requires immediate treatment (within 36 h) with immobilization and the decompression including corticosteroids and urgent surgery followed by chemotherapy and/or radiotherapy.
vena cava superior syndrome
When blood flow from the vena cava superior (VCS) to the right atrium is obstructed, the result is a constellation of symptoms and signs known as the VCS syndrome. The syndrome results from compression of VCS by surrounding tumor, invasion of the vein by tumor masses with concomitant thrombosis or thrombosis only.
Patients with VCS syndrome present with swelling of the head, face and neck. A feeling of fullness and dyspnea symptoms are frequently worse with lying down or bending over.
The most common physical findings are dilated neck veins, facial edema, dilated chest wall veins and cyanosis.
The diagnosis is generally easy to make on history and physical examination alone. VCS syndrome can be distinguished from congestive heart failure and cardiac tamponade by the lack of lower extremity edema, signs and symptoms of respiratory obstruction. Neurological symptoms are rare but important to assess. It is in these patients that the superior vena cava syndrome becomes a true emergency requiring immediate therapy.
Chest X-ray in patients with VCS syndrome is usually abnormal. Up to 15% of the X-rays, however, can be normal in the setting of obstruction of the VCS either because of a benign etiology, thrombosis or more commonly because a thoracic malignancy is not well visualized. CT scan is the most frequently used modality to confirm the diagnosis. A biopsy must be taken from the tumor bulk e.g. by CT-guided biopsy or mediastinoscopy. An accurate diagnosis is a prerequisite for tailored treatment.
In 95% of superior vena cava obstruction the etiology is a malignancy. Sixty-five percent are due to lung cancer and 15% lymphomas. Other cancers include breast, germ cell, carcinoma and thymoma.
skin manifestations
Amyloidosis frequently involves blood vessels of the skin and causes increased vascular and skin fragility and bleeding from minimal trauma.
Lymphoproliferative disorders producing monoclonal IgG and IgM with cryoactivity may produce skin bleeding and ischemia or necrotic lesions when exposed to cold environmental temperatures. A careful examination for the presence of cryoglobulin with protein electrophoresis and immunofixation is necessary.
Vasculitis may be another skin manifestation associated with various lymphoproliferative disorders.
Various T-cell malignancies might be associated with nodular or diffuse infiltration of the skin by the malignant cells. Sézary's syndrome is often accompanied with intense redness of the skin including pruritus. Skin infiltration of B-cell lymphomas is rare.
laboratory abnormalities in asymptomatic patients
altered erythrocyte sedimentation rate and protein abnormalities During a routine clinical evaluation of an asymptomatic individual, the finding of an elevated erythrocyte sedimentation rate (ESR) and/or of an increased or decreased total globulin level leading to further evaluation for an immunoglobulin abnormality is not uncommon (see below). The finding of an increased otherwise unexplained ESR should always include a serum protein electrophoresis.
A serum protein electrophoresis provides a preliminary evaluation of otherwise unexplained globulin abnormalities including other proteins. If immunoglobulins are increased one must first determine whether the increase is polyclonal (arising from multiple clones) or monoclonal (arising from a single clone) of lymphoid/plasma cells. In a polyclonal gammopathy caused by an infection or inflammatory condition, the c-globulin fraction is diffusely increased, resulting in a broad c-globulin fraction. If the increase is monoclonal, a narrow heightened band on the electrophoresis is seen. The finding of a monoclonal gammopathy raises the question of a malignant lymphoproliferative disorder.
Immunoglobulin disorders can be considered in three categories: polyclonal gammopathy, hypogammaglobulinemia and monoclonal gammopathy.
Polyclonal gammopathy is a heterogeneous increase in globulins. In Table 3 the most frequent diseases associated with polyclonal gammopathies are depicted. Oligoclonal expansions may be associated with e.g. hepatitis, endocarditis and leishmaniasis.
Recurrent pyogenic infections are common presentations of patients with hypogammaglobulinemia. Disorders associated with hypogammaglobulinemia are also shown in Table 3 . In the same table also causes of monoclonal gammopathies are shown.
Extremely low ESR (<1 mm/h) may indicate the diagnosis of polycythemia vera.
anemia Anemia is defined as a hemoglobin concentration <120 g/l in men and <110 g/l in fertile women. A decrease in hemoglobin level reduces the oxygen-carrying capacity of the blood, which can result in a variety of symptoms and physical findings. In the absence of organ dysfunction and with a slow onset of the anemia even elderly patients can tolerate hemoglobin levels as low as 70 g/l.
Patients with anemia may be a diagnostic challenge. Is the anemia due to blood loss or not? The most common causes of blood loss are gastrointestinal bleedings.
Microcytic anemias (low MCV) usually arise from a defect in hemoglobin synthesis and are often associated with hypochromia. The most common causes of microcytic anemia are iron deficiency (nutritional or bleeding) and thalassemia.
Macrocytic anemia (increased MCV) includes folate and B 12 deficiency (nutritional, gastric surgery, celiac sprue, perniciosa), drug-induced damaged of DNA synthesis (e.g. chemotherapy), myelodysplastic syndrome, alcoholism, liver disease and hypothyroidism.
Normocytic anemias include a lot of possible causes including anemia of chronic diseases. When the anemia is associated with an increased reticulocyte count, the bone marrow is responding appropriately to e.g. blood loss, sequestration in the spleen [hypersplenism/splenomegaly (see above)] or increased red cell destruction (hemolysis). Intravascular or extravascular hemolysis is supported by the findings of an increased lactate dehydrogenase and bilirubine as well as decreased haptoglobin.
Hemolytic anemias can be immune or nonimmune. Autoimmune hemolysis may be due to warm or cold antierythrocyte antibodies. Nonimmune hemolyses are divided into extracorpuscular (microangiopathic hemolytic anemia, burns, etc.) and intracorpuscular (defects in the RBC e.g. spherocytosis, PNH, sickle cell anemia, thalassemia and various enzyme deficiencies).
An inappropriately low reticulocyte count indicates a problem with bone marrow production of red cells. In normochromic normocytic anemias a low reticulocyte count can be due to the anemia of a chronic disease, developing iron deficiency anemia (before it becomes hypochromic and microcytic), aplastic anemia or pure red cell aplasia. In the latter two diseases, the reticulocyte count is severely reduced.
leukocytosis and leukocytopenia
Abnormalities in the relative and absolute concentrations of peripheral blood leukocytes frequently provide clues to an underlying diagnosis.
neutrophilia and neutropenia
Infections, inflammatory disorders and ischemia with tissue necrosis and trauma are the most common causes of neutrophilia. Other causes are clonal myeloproliferative disorders (CML, CMML, polycythemia vera, myeloid metaplasia and myelofibrosis). Hodgkin's disease might also be associated with neutrophilia. There are also a variety of nonhematopoietic malignancies that are associated with neutrophilia as e.g. lung, renal and bladder carcinoma.
Smoking may induce neutrophilia. There are also individuals with increased neutrophils (10-20 · 10 9 /l) with no detectable disease and this should be regarded as idiopathic.
Occasionally, patients with solid tumors or severe infections may have striking elevations in the leukocyte count (50-100 · 10 9 /l) with increased numbers of immature myeloid cells called leukemoid reaction. The inexpensive cytochemical staining for leukocyte alkaline phosphatase (LAP) can be useful. It is elevated in reactive leukocytosis and low in CML. Increased LAP, however, can also be seen in polycythemia vera and myeloid metaplasia.
Absolute neutrophil counts between 1.0 and 1.5 · 10 9 /l are considered mild neutropenia and may be associated with an augmented risk of infections, which increases by increased duration. Patients with 0.5-1.0 · 10 9 /l have a moderate risk of infection while those with <0.5 · 10 9 /l carry a high risk of bacterial and fungal infections depending also on the duration of the neutropenia.
Causes for neutropenia are infiltration of malignant cells in the bone marrow, viral infections, alcohol, drugs, splenomegaly with sequestration, autoimmune diseases, lymphoproliferative disorders with and without splenomegaly as hairy cell leukemia and T-cell large granular lymphocytosis, myeloid and acute leukemias.
lymphocytosis and lymphocytopenia
The initial evaluation of the lymphocyte count should include whether the total lymphocyte count is below or above the normal range (1 to 4-5 · 10 9 /l.). The term relative lymphocytosis should be abandoned. Relative lymphocytosis does in fact reflect neutropenia. When increased numbers of atypical lymphocytes accompany neutropenia, the differential diagnosis should include viral infections.
Lymphocytosis is defined as >4-5 · 10 9 /l lymphocytes. In adolescents, infectious mononucleosis is the most common cause. A cell smear shows remarkable pleiomorphic lymphocyte morphology with monocytoid features. Concerns about an underlying lymphoid malignancy can be strengthened further by complications as thrombocytopenia and hemolytic anemia, but mononucleosis might also present with such signs. Generally, review of the peripheral blood smear and the confirmatory serologic test for Epstein-Barr virus (EBV) antibodies will lead to the correct diagnosis. If EBV titers are negative, tests for antibodies to CMV and toxoplasmosis should be included.
In adults, lymphocytosis should raise concerns about clonal lymphoproliferative disorders. The presence of splenomegaly and peripheral lymphadenopathy will reinforce that concern. Immunophenotyping by flowcytometry is the simplest initial diagnostic approach including phenotyping for a monoclonal B-cell population (K : k ratio)
The overwhelming majority of adult patients with an adult lymphocytosis will have a clonal B-cell disorder. Most of the patients will have B-CLL. It should be kept in mind that also a lot of patients presenting with 5-10 · 10 9 /l lymphocytes might have phenotypically normal lymphocytes. Such a slight increase in the lymphocyte count might be a reaction towards an external stimuli or be considered idiopathic in analogy to neutrophilia. Other possible B-cell disorders are Waldenström's macroglobulinemia, prolymphocytic leukemia, mantel cell lymphoma, follicular lymphoma, hairy cell leukemia and marginal zone lymphoma.
If the clonal lymphocytes have a T-cell phenotype, the following causes should be considered: cutaneous T-cell lymphoma (Sézary's syndrome, adult T-cell leukemialymphoma, T-cell large granular lymphocytosis, prolymphocytic leukemia and peripheral T-cell lymphoma). Lymphocytopenia might be an initial sign indicating Hodgkin's disease.
thrombocytosis and thrombocytopenia
Abnormalities in platelet numbers are commonly observed in routine blood counts. The finding of an elevated or decreased platelet count may indicate a primary bone marrow disorder or reflect other underlying medical problems.
The initial evaluation of patients with platelet counts above or below normal levels should include: (i) the extent of increase or decrease from normal levels, (ii) associated changes in red and white blood cells; (iii) the presence of related symptoms and (iv) the duration if possible of the platelet count abnormality.
thrombocytopenia Although it is difficult to give the exact risk of bleeding for a thrombocytopenic patient the following guidelines might be of value. Platelet counts >50-100 · 10 9 /l result usually in normal hemostase. Platelet counts 10-50 · 10 9 /l normally have no increased risk of spontaneous bleeding but may have an increased risk of surgical bleeding. Both these two groups, however, might have an increased risk of bleeding in connections with infections and when taking aspirin. Platelet counts <10 · 10 9 /l are related with an increased risk of spontaneous bleeding and significant bleeding at surgery.
Diagnostic procedures of thrombocytopenia depend on symptoms and platelet count. Symptomatic patients with moderate to severe thrombocytopenia (<50 · 10 9 /l) and concomitant anemia and/or leukocytopenia require a complete evaluation. The extent of the evaluation of mild thrombocytopenia (50-130 · 10 9 /l) in asymptomatic patients remains one of the physician's decisions.
Patients with a long standing and mild thrombocytopenia (100-130 · 10 9 /l) require no specific evaluation except for medications, assessment of spleen size, peripheral blood evaluation, autoimmune testing and ESR. If all normal, it might be recommended to follow such patients for 2 years every sixth months. If the condition is stable then no further follow-up is necessary.
Asymptomatic patients with 50-100 · 10 9 /l of platelets should be evaluated as above but also include renal and liver function tests, fibrinogen, PT and PTT and D-dimers to exclude chronic DIC. If these are unremarkable, patients should be followed every 3-6 months for 2 years, then up to the discretion of the responsible physician.
In patients with thrombocytopenia (<100 · 10 9 /l) of unknown causes the following diagnoses should be ruled out: thrombotic microangiopathy, acute DIC and acute bleeding. Patients with renal dysfunction and/or central nervous system symptoms require an immediate evaluation.
Most thrombocytopenic patients do not require a bone marrow biopsy. The rationale for performing a bone marrow analysis is to assess adequately the bone marrow stores of megakaryocytes as well as to observe any associated red or white cell disorder.
In most cases of thrombocytopenia antiplatelet antibody tests are of little help. Table 4 summarizes most causes of thrombocytopenia.
thrombocytosis Disorders of elevated platelet counts are divided into benign reactive causes and malignant causes usually due to myeloproliferative disorders and occasionally myelodysplastic syndromes. The benign causes are not associated with increased clotting risks and are usually an acute phase reaction ('thrombocytosis'). The malignant causes ('thrombocythemia') have an increased thrombotic and bleeding risk. Most cases of elevated platelet causes are 'reactive'.
Patients with a persistent elevated platelet count >500 · 10 9 /l warrant evaluation to distinguish reactive thrombocytosis from thrombocythemia. The most frequent causes of elevated platelet counts are shown in Table 5 .
hypercalcemia Hypercalcemia occurs in 20 per 100 000 population and is therefore not an infrequent finding in routine blood chemistry analyses in asymptomatic individuals. Although hypercalcemia can occur as a paraneoplastic syndrome it rarely occurs in the absence of symptoms from the hypercalcemia itself and from the underlying malignancy. In symptomatic patients it is important to establish whether the symptoms originate from the hypercalcemia itself or from the underlying disease. Usually the differential diagnosis between a benign and malignant etiology of hypercalcemia can be accomplished on the basis of history, symptoms, clinical findings and/or the presence of other blood test abnormalities.
Hypercalcemia of malignancy is diagnosed in 20%-40% of cancer patients at some time during the course of their disease. Hypercalcemia is frequently encountered in patients with breast, non-small-cell lung and renal cancer as well as in multiple myeloma and lymphoma.
Different etiologies of hypercalcemia are listed in Table 6 . Signs and symptoms of hypercalcemia of a malignant disorder are nonspecific and can develop acutely or as a subacute symptomatic or chronic asymptomatic disorder. Symptoms include anorexia, nausea, vomiting, constipation, dehydration and neurological symptoms as weakness, depression, apathy, or coma. Hypercalcemia causes renal tubular damage resulting in impairment of the concentrating ability and natriuresis leading to polyuria, dehydration, and rising creatinine. These renal events and dehydration further contribute to the elevation of the calcium level. Electrocardiograms mostly reveal a shortened QT interval and the patient may also develop cardiac arrhythmias.
Laboratory evaluation should include total and ionized calcium, phosphorous, electrolytes, magnesium, urea, creatinine and serum albumin. 
